Skip to main navigation
Optinose
  • Join Our Team
  • Contact Us
  • Company
    • Our Purpose
    • Company History
    • Leadership Team
    • Board of Directors
    • Partnership Opportunities
    • Corporate Compliance
  • Exhalation
    Delivery Systems
    • Liquid Delivery
    • Powder Delivery Device
    • Anatomy of the Nasal Passages
    • Nasal Delivery Challenges
  • Therapeutic
    Areas
  • Products
    • XHANCE®
    • ONZETRA® Xsail®
  • Research &
    Development
    • XHANCE® - Future Development
    • Partnerships
  • Investors
    • News & Events
    • Stock Information
    • Corporate Governance
    • SEC Filings
    • Proxy Materials
    • Investor Resources
  • News &
    Media
  • Scientific
    Communications
    • Peer-Reviewed Journal Publications

News Releases


News Releases

Keyword Search

Date Title  
03/07/23
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
Printer Friendly Version
02/28/23
Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results
Printer Friendly Version
02/21/23
Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
Printer Friendly Version
01/31/23
Optinose Announces CEO Transition and Business Update
Printer Friendly Version

Investors

  • News & Events
    • News Releases
    • Event Calendar
    • Presentations
  • Stock Information
  • Corporate Governance
  • SEC Filings
  • Proxy Materials
  • Investor Resources

Toolkit

  • Printer Friendly Version Print page
  • E-mail Alerts Sign up for email alerts

  • Investor Contact

    Jonathan Neely
    VP Investor Relations and Business Operations
    Email: investors@optinose.com
Contact Us
P.O. Terms & Conditions
Join Our Team
Privacy Policy
Terms of Use
Site Map
Footer Logo
©2023 Optinose. OPTINOSE-17-013a 09/2017